COPCOV is a multi-country study to test the effectiveness of chloroquine or hydroxychloroquine to prevent COVID-19 in healthcare workers, who have a higher risk of illness because of potential workplace exposure to the virus.
Primary objective: To determine if chloroquine or hydroxychloroquine prophylaxis prevents symptomatic COVID-19 infection in healthcare workers
Type of study: Interventional; Phase III, pre-exposure prophylaxis
Treatment tested: Chloroquine, hydroxychloroquine
Countries: confirmed or potential: Europe (UK, Italy, Portugal, Luxembourg, Croatia), Asia (Thailand, Malaysia, Lao PDR, Viet Nam, Indonesia, Pakistan), Africa (Kenya, Niger, Ghana, Zambia, Cameroon, DR Congo)
Number of sites: 100
Sample size: 40,000
Study participants: Healthcare workers in a healthcare facility delivering direct care to patients with either proven or suspected COVID-19. Adults (exact age is dependent on local country requirements).
Study status: Active, not recruiting
Last updated: June 2020
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.